This activity was originally broadcast live at the CPNP 2022 Annual Meeting.
Program Description
Clinical consequences associated with uncontrolled symptoms of schizophrenia present treatment challenges and can increase disease burden for both patients and health care providers. Recognizing treatment challenges, including nonadherence to therapy or suboptimal therapy, and identifying potential strategies to improve adherence are essential to prevent disease relapse and improve overall patient outcomes. Pharmacists have an important role in the treatment of schizophrenia by helping to choose initial therapy according to patient-specific factors, addressing suboptimal therapeutic responses, and mitigating adverse effects. The current treatment landscape of schizophrenia continues to evolve with novel therapies and routes of administration, offering pharmacists more opportunities to make treatment interventions to improve patients’ symptom control, improve adherence, and address treatment-related challenges. This program will review updated clinical guidelines, efficacy and safety of newer treatment strategies, and considerations for their administration in both inpatient and outpatient clinical practice settings.
Target audience: Health-system pharmacists, retail pharmacists, and specialty pharmacists
Type of activity: Application
Release date: May 17, 2022
Expiration date: May 17, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the current and emerging data on the disease burden and progression of schizophrenia
- Discuss current evidence-based guidelines, newly emerging agents, and therapeutic challenges in schizophrenia
- Identify the role of the pharmacist in addressing treatment challenges in schizophrenia, including patient education and optimizing adherence
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
